Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies.
The association between ante mortem [(11)C]-Pittsburgh Compound B (PiB) retention and β-amyloid (Aβ) load, Lewy body (LB) and neurofibrillary tangle (NFT) densities were investigated in a pathologically confirmed case of dementia with Lewy bodies (DLB). A 76 year old man presenting with a clinical diagnosis of DLB had undergone PiB-positron emission tomography (PET), (18)F FDG-PET and magnetic resonance imaging (MRI) 18 months before death. The pathologic diagnosis was DLB neocortical-type with low-likelihood of Alzheimer's disease by NIA-Reagan criteria. Sections from regions of interest (ROI) on post-mortem examination were studied. A significant correlation was found between cortical Aβ density and PiB retention in the 17 corresponding ROIs (r = 0.899; p < 0.0001). Bielschowsky silver stain revealed mostly sparse neocortical neuritic plaques, whereas diffuse plaques were frequent. There was no correlation between LB density and PiB retention (r = 0.13; p = 0.66); nor between NFT density and PiB retention (r = -0.36; p = 0.17). The ROI-based analysis of imaging and histopathological data confirms that PiB uptake on PET is a specific marker for Aβ density, but cannot differentiate neuritic from diffuse amyloid plaques in this case with DLB.
Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. kantarci.kejal@mayo.edu
Kejal
K
Kantarci
Chunhui
C
Yang
Julie A
JA
Schneider
Matthew L
ML
Senjem
Denise A
DA
Reyes
Val J
VJ
Lowe
Lisa L
LL
Barnes
Neelum T
NT
Aggarwal
David A
DA
Bennett
Glenn E
GE
Smith
Ronald C
RC
Petersen
Clifford R
CR
Jack
Bradley F
BF
Boeve
D000368:Aged; D016229:Amyloid beta-Peptides / Q000009:adverse effects* / Q000096:biosynthesis; D000814:Aniline Compounds; D002250:Carbon Radioisotopes; D017809:Fatal Outcome; D006801:Humans; D020961:Lewy Body Disease / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D008297:Male; D019579:Neocortex / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D019696:Peptidylprolyl Isomerase / Q000037:antagonists & inhibitors; D010618:Phenanthrolines; D049268:Positron-Emission Tomography / Q000379:methods*; D013844:Thiazoles
C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D002250:Carbon Radioisotopes; D010618:Phenanthrolines; D013844:Thiazoles; D019696:Peptidylprolyl Isomerase